Abstract. Accumulating evidence indicates that alterations in glial activation and disturbances in glial glutamate metabolism may contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS). Metabotropic glutamate receptors (mGluRs) are involved in glutamate homeostasis as well as in glial proliferation. Using in situ hybridization and immunohistochemistry we found a strong upregulation of group I and group II mGluR mRNA and protein in ALS spinal cord as compared to controls (mGluR5 Ͼ mGluR1 Ͼ mGluR2/3). In vitro, the mGluR group I agonist 3,5-dihydroxyphenylglycine induced proliferation in chick spinal cord astroglial cultures. Moreover, addition of cerebrospinal fluid (CSF) from ALS patients resulted in significantly higher proliferation rates than control CSF. In both cases, the effect could be blocked by addition of the mGluR group I antagonist 1-aminoindan-1,5-dicarboxylic acid. Taken together, our data suggest that stimulation of glial mGluRs through mediators present in the CSF may contribute to glial proliferation and astrogliosis in ALS.
INTRODUCTION
Prominent astrogliosis and degeneration of the motoneurons in the cortex and the spinal cord are the most characteristic histopathologic features in amyotrophic lateral sclerosis (ALS) (1, 2) . Traditionally, astrogliosis was thought to be secondary to motoneuron loss and subserve the function of replacing degenerated tissue to form a gliotic scar. However, increasing evidence indicates that glial dysfunction may be crucially involved in the pathogenesis of ALS. Glial proliferation has been identified as an event occurring as early as motoneuron death in a transgenic model (3, 4) , and microscopic studies showed that activated astrocytes have close interactions with degenerating motoneurons (5) . Moreover, disturbances in glial glutamate transport and metabolism may contribute to excitotoxic mechanisms (6) . In addition to glutamate transporters, glial cells express ionotropic as well as metabotropic glutamate receptors (mGluRs) (7, 8) .
The 8 mGluR subtypes known today are categorized in 3 groups according to their second messenger coupling, sequence similarities, and agonist interactions. Group I comprises mGluR1 and 5, group II mGluR2 and 3, and group III mGluR4, 6, 7 and 8. The predominant subtypes expressed in astrocytic cultures from most brain From Department of Neurology (JMHA, CC, GDB), Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; Academic Neuropathology Unit (PGI) and Academic Neurology Unit (PJS), University of Sheffield, Sheffield, United Kingdom.
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regions are mGluR3 and mGluR5 (7) (8) (9) . However, Silva et al found the most intense signals in spinal cord astrocytic cell cultures with antibodies directed against mGluR1 and mGluR2/3 (10) . Only weak signals for the remaining mGluR mRNA were occasionally detected in astrocytic cDNA by Biber et al (7) . Correspondingly, histopathological studies revealed that mGluR3 is the predominant subtype expressed in glial cells of the brain (11, 12) and spinal cord as shown by in situ hybridization (13) . Thus, groups I and II mGluRs appear to be the most frequently-if not the only-mGluRs expressed in astrocytes under physiologic conditions. Dynamic changes of mGluR expression can be observed in vitro and in vivo. Specific growth factors upregulate mGluR expression in astrocytes in vitro (14, 15) , while thrombin has a negative effect on glial mGluR expression (16) . In vivo, an increased expression of mGluR3 and 5 has been reported recently in acute brain lesions caused by kainate application and electrical hippocampal stimulation (17, 18) . These findings suggest an important role of mGluRs in glial function and proliferation. Hence, we investigated mGluR expression in gliotic areas in ALS spinal cord. Furthermore, we established an in vitro model to test the role of mGluRs in glial proliferation in ALS.
MATERIALS AND METHODS

CNS Samples and Tissue Preparation
Cryo-preserved spinal cord tissue was taken from 5, freshfrozen tissue samples from 4 cases of ALS, clinically matching the El Escorial criteria of probable or definite ALS, and the respective number of control cases. For patient details see the Table. At postmortem, tissue blocks were dissected and snapfrozen for in situ hybridization or subjected to a cryo-preservation protocol, and stored as described previously (20) . Histograms showing signal intensities of controls (gray bars) and ALS patients (black bars) detected with in situ hybridization (A) and immunohistochemistry (B). Significant increases in expression levels were found for mGluR1, mGluR3 and mGluR 5, while no significant differences were found for GluR2/3 mRNA. **p Ͻ 0.005; ***p Ͻ 0.001.
CSF Samples
CSF was taken from 10 patients with probable or definite ALS without medication for this disease and 10 control patients with headache for exclusion of subarachnoidal hemorrhage or meningitis, patients with idiopathic Bell's palsy, or peripheral noninflammatory polyneuropathy. All patients gave their informed consent. All CSF samples had normal values for protein, glucose, and cells and were negative for oligoclonal bands. CSF samples were centrifuged and frozen immediately after the spinal tap had been performed.
Immunohistochemistry (IHC)
A free-floating technique was used for single and double labeling as described previously (19, 20) . Briefly, sections were cut at 30 m and placed in 0.9% hydrogen peroxide in PBS to quench endogenous peroxidase activity, treated with blocking serum, and incubated at 4ЊC with primary antibody overnight. Sections were then incubated with biotinylated horse antimouse (GFAP) or biotinylated goat anti-rabbit (mGluRs) secondary antibody (Vector Laboratories, Burlingame, CA).
After treatment with ABC reagent (Vectastain Elite ABC kit, Vector Laboratories), antibody binding was demonstrated by incubation of sections with 3Ј,3-diaminobenzidine tetrachloride (0.025%), hydrogen peroxide (0.02%), and nickel sulphate (2.5%) in acetate buffer (0.1 M, pH 6.0). The sections were then washed, dehydrated through graded ethanol, and mounted on Vectabond-treated slices (Vector Laboratories). Sections from ALS patients and controls were processed under identical conditions in the same IHC run.
Double Labeling: For double labeling studies, brain or spinal cord sections were treated with blocking serum and incubated with the monoclonal anti-GFAP antibody for 2 h at room temperature. After a washing step, the sections were incubated with biotinylated anti-mouse antibody (Vector Laboratories). The sections were washed, placed in ABC-AP reagent (Vestorstain ABC-AP kit, Vector Laboratories), and washed again. For color reaction, sections were incubated with Vector Red reagent (Vector Red substrate kit, Vector Laboratories). mGluR immunohistochemistry was then performed as described above.
Immunoblot Analysis: For immunoblot analysis, cells were collected, homogenized in lysis buffer containing protease inhibitor cocktail (Roche Diagnostics, Grenzach-Wyhlen, Germany). Protein content was determined by using the nanoquant method. Homogenates were diluted in 4ϫ NuPAGE sample buffer (Invitrogen, San Diego, CA) and heated to 70ЊC (10 min). Equal amounts of protein (0.03 mg/ml) were loaded on a (3%-8%) Tris-acetate gel (Invitrogen). Electrophoresis and blotting was performed according to manufacturer's instructions (NuPage, Invitrogen). Samples were then incubated overnight at 4ЊC with primary antibodies. Immunoreactive bands were then visualized using alkaline phosphatase-conjugated secondary antibodies and a chemoluminescent immunodetection kit (WesternBreeze, Invitrogen). Equal protein loading was revealed by Ponceau staining of the membranes.
Antibodies: A specific antibody was used to recognize astrocytes (monoclonal anti-GFAP antibody, Roche Diagnostics) and proliferating astrocytes (monoclonal anti-vimentin, Sigma, St. Louis, MO). Polyclonal anti-mGluR1, mGluR2/3, and mGluR5 antibodies were purchased from Chemicon (Temecula, CA). 
In Situ Hybridization
Transverse sections (14 m) were cut from spinal cord and brain blocks at Ϫ20ЊC and processed for in situ hybridization as described previously (21) . Triplets of oligonucleotides (43-mers) directed against mGluR1,2,3, and 5 were labeled with [␣- 35 S] dATP (1200 Ci/mmol; New England Nuclear/Perkin Elmer, Wellesly, MA) using terminal transferase (Roche Diagnostics) and a 30:1 molar ratio of dATP:oligonucleotide. The sections were hybridized in 50% formamide, 4ϫ saline sodium citrate (SSC), 10% dextran sulfate at 42ЊC for 12 h and washed in 1ϫ SSC at 55ЊC.
mGluR1
The sequences used were as follows: 5Ј-TCC AAC GTG CAC ATA GTC ATA GCG ATT AGC TTC AGT GTA CTG-3Ј 5Ј-AAT GGG CTT CTT AGT CCT GCC TGG GGG GAG GGA CTG GCC GTC-3Ј 5Ј-TGA AGG CAC TGC GGA CAT TCC TCT CAG GCT TGG CAA TAA TGA-3Ј
mGluR2
The sequences used were as follows: 5Ј-CAG GGG GCC GGC TGA CGG TGA GGC CCA TGG GAT GAG GCT GGT-3Ј 5Ј-GTG GAG GCA CCG GGC ACA GGC AAG GAG ACA GCC CCC GAA CGG-3Ј 5Ј-TTC CGG CAG CGA GAC TGC GCA GCC CACTCT CTC CGG GCT GTG-3Ј
mGluR3
The sequences used were as follows: 5Ј-TGA TTC GCC  CAC ATT CTT CAG TTC CAG TGC CTT TTT CGT TAT-3Ј  5Ј-TAT TTT AAT CTC TCT CCT TAG AAA GTT ATG GTC  CCC TAA AGA-3Ј 5Ј-TTT CAA GTA GGA ATA CTT TCC  ACC TAC ATT TTG GAA ATT GAA-3Ј   mGluR5 The sequences used were as follows: 5Ј-TAC TAT GGG CTT  CTT GGA GCG GAA GGA AGA GGA GGA GCC ATC-3Ј  5Ј-GGA CCA TAC TTC ATC ATC ATC CAT TTT TAA TTC  TCC ATT GTC-3Ј 5Ј-TAA GGT TTC CCC AGA GGA GCC  CCT TCT CTT CCA CAG GTT GAC-3Ј The slides were dipped in Kodak (Stuttgart, Germany) autoradiography emulsion (NTB2), exposed for 7 weeks, and counterstained with cresyl violet. Nonspecific labeling was assessed by incubating sections with a 100-fold excess of unlabeled probe together with the corresponding [␣- 35 S] dATP-labeled probe. The resulting signal was indistinguishable from background (not shown).
Chick Glial Cultures
For cell culture, chick embryos (embryonic day 8) spinal cords were removed and trypsinated as described elsewhere (22) . Cell separation was performed via a metrizamide gradient (23) . The pellet was seeded and cells were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen/Gibco, San Diego, CA) and 10% horse serum (Invitrogen/Gibco) to confluency. After 8 days, more than 95% of the cells stained positive with anti-GFAP-antibody (data not shown). Confluent cultures were then starved for 48 h in serum free medium. CSF and/or mGluR agonists were added for 48 h prior to Western blot analysis or BrdU staining. mGluR agonists and antagonists were added at a concentration of 100 mol. For CSF experiments, 10% control or ALS CSF was supplemented to the culture medium.
BrdU Staining
BrdU staining was performed according manufacturer's instructions (In situ cell proliferation kit, FLUOS, Roche). Briefly, BrdU-labeling solution was added to culture medium for 1 h. Cells were fixed with an ethanol-glycine solution and denatured with 4 M HCl. Incorporated BrdU was then detected using a fluorescein-conjugated anti BrdU monoclonal antibody.
Data Analysis
Quantitative analysis was performed using a digital image analysis system (Zeiss KS 300, Zeiss, Jena, Germany) fitted with an Olympus microscope and a Zeiss camera (AxioCam). For ISH and IHC, 2 sections of the ALS or control patient were analyzed. Representative areas of both ventral horns were selected. Measurements were made by determining the area covered by silver grains (ISH sections) or by immunohistochemically stained glial cells (IHC sections). ISH measurements were corrected for background signal.
For analysis of BrdU-stained cultures, 3 slides per experiment were analyzed. In CSF experiments, independent runs with 3 different ALS or control samples were used. Three randomly chosen areas of each slide were acquired by the imaging system. Measurements were made by counting the number of BrdU-positive cells per area.
Statistical Analysis
All data are presented as mean Ϯ SD. Where appropriate, the Student t-test (two-tailed) was performed to assess significance.
RESULTS mGluR Expression in Control Patients
Using IHC, glial mGluR group I and II protein in spinal cord glial cells of control patients was virtually absent ( Fig. 1B) , while ISH revealed moderate levels of mGluR1 and mGluR3 (Fig. 1A) . mGluR2 and mGluR5 mRNA was barely detectable in human spinal cords. Staining with anti-GFAP antibodies revealed very low expression levels in controls (not shown). All mGluR subtypes investigated were found to be expressed in neuronal somata as well as in dendrites and axons (Fig. 2) . There was little mGluR signal visible in white matter regions, and there were no differences between the pyramidal tract and other white matter regions (not shown).
mGluR Expression in ALS Patients
Highly significant differences between ALS patients and controls were detected with all anti-mGluR antibodies used in this study (Fig. 1B) . The highest signal intensities in ALS spinal cord ventral horns were found with anti-mGluR5 antibodies, followed by anti-mGluR1 and anti-GluR2/3. Colocalization studies with the astrocytespecific marker GFAP revealed that mGluR-positive cells in the spinal cord and the subcortical white matter were mainly astrocytes (Fig. 3E) . The spinal cord reactive astrocytes were also positive for vimentin staining and were often in close contact with motoneurons (3F). Quantitative analysis in consecutive spinal cord sections showed that the amounts of mGluR5 and GFAP-expression are highly positively correlated (Fig. 4) . However, in gliotic areas, mGluR5-positive macrophages were found sporadically.
The increases in mGluR protein levels were paralleled by increases in mRNA amounts as revealed by ISH (Fig.  5) . The highest mRNA quantities were detected for mGluR5, followed by mGluR1, while there was a moderate increase in mGluR3 mRNA (Figs. 1A, 6 ). No significant difference in mGluR2 mRNA could be found between ALS-patients and controls in our study (Fig. 1B) .
The increase in mGluR expression was most prominent in the ventral horn in vicinity of the degenerating motoneurons (Fig. 6 ), but strong mGluR signals could be seen also in small cells (most likely glial cells) of other spinal cord regions. Staining of the pyramidal tract was visible throughout of the whole spinal cord and brainstem (Fig.  3A, B ) and was present with all mGluR antibodies used. In the subcortical white matter, large stellate glial cells were observed in ALS patients that were positive for mGluR1, mGluR2/3, and mGluR5 (Fig. 3D) . No quantification of the signal in the pyramidal tract or the subcortical white matter was performed in this study. Neuronal mGluR expression, including the surviving motoneurons, appeared to be unchanged, and the low number of surviving motoneurons in ALS spinal cord did not allow us to compare motoneuronal mGluR expression between patients and controls.
mGluRs Mediate Astrocytic Proliferation In Vitro
Using chick spinal cord astrocytic cultures, we observed a significant increase in proliferating cells after addition of a group I agonist (DHPG) to serum-deprived glial cells. This effect could be blocked by the mGluR group I antagonist AIDA (Fig. 7) . A moderate, not significant increase of BrdU-positive cell staining was observed after addition of the mGluR group II agonist DCG-IV. These results could be confirmed by immunoblotting techniques that revealed an increase of vimentin expression after addition of DHPG and DCG-IV (Fig.  7B) .
ALS CSF and Astrocytic Proliferation
Addition of 10% ALS CSF to our primary spinal cord glial cultures resulted in a significantly higher increase in proliferation rates compared to CSF from control patients, as evidenced by the number of BrdU-positive cells (Fig. 8A, C) . Similarly, addition of ALS CSF resulted in greatly enhanced vimentin expression, as shown by immunoblotting (Fig. 8B) . Furthermore, we found a reduction in proliferation rates after addition of the mGluR group I antagonist AIDA to both treatment groups (57% and 45% respectively, Fig. 9A ), suggesting that the proliferation promoting action of control CSF and ALS CSF was at least partly mediated by mGluR activation. This result is reflected by a reduction in vimentin expression as shown by immunoblotting (Fig. 9B) . The anti-proliferative effect of AIDA was significantly higher in ALS CSF-treated cultures compared to control CSF-treated cultures (p Ͻ 0.01). However, using immunoblotting and immunocytochemistry, no significant differences in mGluR group I expression could be detected in cultures treated with ALS CSF compared to those treated with control CSF (not shown).
DISCUSSION mGluR Expression in ALS and Control Spinal Cord
We have described an upregulation of protein and mRNA for group I and II mGluRs in glial cells from the spinal cord of ALS patients. Control patients expressed only moderate levels of mGluR1 and mGluR3 mRNA in spinal cord glial cells, while GluR2 and GluR5 were barely detectable. This is in accordance with in vitro results described previously by Silva et al (10) : A robust expression of mGluR1 and mGluR2/3 was detected in cultured spinal cord astrocytes, while other subtypes were absent. Hence, expression of mGluR1 seems to be specific for spinal cord glia, since it has not been detected in astrocytes from other regions (7, 24, 25) . However, despite moderate mGluR1 and mGluR3 mRNA levels observed in control patients, mRNA levels were not paralleled by IHC signal intensities, which were equally low with all antibodies used. Similar discrepancies between mGluR mRNA expression and protein contents were described by Ciccarelli et al (24) : In cultured cortical astrocytes mGluR3 mRNA is found by RT-PCR, while the same mGluR2/3 antibody that was used in our study revealed no signal with immunoblotting techniques. Differences in mRNA turnover or translation may account for these differences. Alternatively, glial cells may express a mGluR2 with modifications at the carboxy-terminus, which is recognized by the mGluR2/3 antibody.
A remarkable increase in mGluR expression was found in all ALS spinal cords examined. However, large variations in glial mGluR expression levels from patient to patient were observed. Similar to the variable extent of astrogliosis in ALS patients, which has been described previously (2) , this observation may reflect differences in the disease stage and/or the severity of the segmental pathology of this disease. Accordingly, we could show that mGluR expression parallels the degree of astrogliosis, since mGluR5 and GFAP-expression are highly positively correlated (Fig. 4) .
In our experiments, age and postmortem delay did not differ significantly between ALS and control samples (Table) . In addition, the postmortem delay in both groups did not correlate with ISH or IHC signal intensities. Therefore, it seems unlikely that upregulation of mGluR expression in ALS postmortem samples might be caused by factors other than the underlying disease.
Interestingly, mGluR1 expression, which seems to be specific for spinal cord astrocytes, is also found to be upregulated in ALS patients. Spinal astrogliosis may therefore have different characteristics compared to reactive glial cells observed in other brain regions (17, 18) .
Our results, showing highest increases in mGluR5 protein levels, followed by mGluR1 and 2/3 (26), differ from semiquantitatively evaluated immunohistochemical findings described by Aronica et al (27) , who reported that mGluR1 is most frequently expressed in ALS ventral horn glial cells, while the number of mGluR 2/3-and mGluR5-positive astrocytes was lower. This may be due to the differences in the affinity of the mGluR5 antibodies used, the method of tissue preservation (cryo-preserved vs paraffin-embedded), or patient characteristics. However, IHC results were confirmed by ISH in our study since specific subtypes were increased in similar proportions with both techniques. The signal increase in ALS patients found with the mGluR2/3 antibody, which cannot distinguish between mGluR2 and 3, is likely to be caused by enhanced expression of mGluR3, since mGluR2 mRNA expression in ALS patient ventral horns was equal to controls.
These results demonstrate a significant upregulation of mGluRs in the spinal cord of ALS-patients. However, from these postmortem data alone, an impact of glial mGluR upregulation for the disease process cannot be deduced. Therefore, we sought to correlate these findings with assessable functional effects of mGluR activation in glial cells.
Glial Proliferation In Vitro
In our postmortem study, mGluR expression was mainly observed in astrocytes showing characteristic morphological changes of reactive glial cells (Figs. 3F, 6 ). Since mGluR activation has been associated with glial proliferation (24, 28), we tested the hypothesis that mGluR activation may contribute to glial proliferation in ALS.
We first investigated whether mGluR agonists enhance cell proliferation in a model of chick spinal cord glial cells. Secondly, we used ALS CSF in these cultures to induce glial proliferation and tested mGluR antagonists for their antiproliferative effects. We observed a significant increase in proliferating cells in chick spinal cord astrocytic cultures after addition of DHPG. This effect could be blocked by addition of the mGluR group I antagonist AIDA (Fig. 7) . However, we could not detect a reduction in proliferation after addition of agonist DCG-IV as observed by Ciccarelli et al (24) , but a moderate, not significant increase of BrdU-positive proliferating cells. These results could be confirmed by Western blotting techniques, which revealed an increase of vimentin expression after addition of DHPG and DCG-IV (Fig.  7b) . The differences between the results described by Ciccarelli et al (24) and our findings may be due to different properties between cortical and spinal astrocytes, perhaps due to expression in mGluR1, which is only found in spinal astrocytes.
Various studies have revealed previously that ALS CSF may exert disease specific properties in cell culture systems. ALS CSF has been shown to be toxic in cortical cell cultures (29, 30) and to increase c-Fos expression in spinal cord slices via a glutamatergic mechanism (31) . Elevated glutamate levels in the CSF of ALS patients have been described in the past, although these results have not been confirmed by all studies (32, 33) . In vivo, intrathecally injected ALS CSF caused reactive astrogliosis in neonatal mice (34) .
Similarly, we found a significant difference in the proliferation rate-as evidenced by counting BrdU-positive cells-in our astrocytic spinal cord cultures between cultures treated with ALS CSF or control CSF (Fig. 8) . Furthermore, we found a reduction in the number of proliferating cells and vimentin expression after addition of the mGluR group I antagonist AIDA to both treatment groups (Fig. 9) , suggesting that the proliferation promoting action of control CSF and ALS CSF was at least partly mediated by mGluR activation. Remarkably, the proportional reduction of proliferating cells due to addition of AIDA was significantly higher in ALS CSF stimulated cells compared to control CSF stimulated cells (57% vs 44%, respectively). However, we could not induce group I mGluR expression after ALS CSF addition to our astrocytic cultures, similar to the mGluR upregulation observed in ALS spinal cord. This may be explained by high mGluR expression in our embryonic culture system. Accordingly, in rat spinal cord, high mGluR1 and 5 levels have been found in young animals with a gradual reduction during development (13) . The glutamatergic proliferative effects of CSF observed in our in vitro experiments may therefore rather be a direct action on mGluRs than an indirect effect due to upregulation of mGluRs.
Our data demonstrate profound alterations in glial mGluR expression in the ALS spinal cord. Furthermore, our in vitro experiments suggest that stimulation of mGluRs may propagate glial proliferation in ALS. In addition to the proliferation promoting effects, mGluR activation has been shown to regulate the expression of glutamate transporters (35, 36) . Glial mGluRs may therefore link astrocytosis and disturbances in glutamate homeostasis, 2 key phenomena observed in ALS. Further studies with SOD transgenic mice, a model of familial ALS, have been initiated to investigate mGluR expression in reactive glial cells during the course of the disease and to test possible pharmacological interventions in this animal model.
